Compare SOTK & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | XLO |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.0M | 56.9M |
| IPO Year | 1995 | 2021 |
| Metric | SOTK | XLO |
|---|---|---|
| Price | $4.25 | $8.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $8.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 105.0K | 13.3K |
| Earning Date | 10-14-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | $20,909,315.00 | ★ $43,766,000.00 |
| Revenue This Year | $2.67 | $3.55 |
| Revenue Next Year | $23.22 | $9.26 |
| P/E Ratio | $62.14 | ★ N/A |
| Revenue Growth | 1.97 | ★ 589.88 |
| 52 Week Low | $3.40 | $0.46 |
| 52 Week High | $7.48 | $22.60 |
| Indicator | SOTK | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 32.35 | 41.60 |
| Support Level | $4.25 | $7.29 |
| Resistance Level | $4.62 | $9.21 |
| Average True Range (ATR) | 0.28 | 0.58 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 11.03 | 45.89 |
Sono-Tek Corp designs and manufactures ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial, and emerging research & development/other markets. The company designs and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.